INOVIO Pharmaceuticals
WEBWe use proprietary technology to design DNA plasmids —small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target and fight disease.
DNA Medicines Technology | INOVIO Pharmaceuticals
WEBOPTIMIZED DESIGN ANDDELIVERY, TEACHING THE BODY TO FIGHT DISEASE. INOVIO uses proprietary technology to design DNA plasmids — small circular DNA molecules that work like software that the body’s cells can download to produce specific proteins to target and fight disease.
DNA Medicines Pipeline | INOVIO Pharmaceuticals
WEBINOVIO is leveraging a cutting-edge platform to advance DNA medicine candidates with the potential to transform disease prevention and treatment paradigms and improve patients’ lives. Inovio’s product pipeline continues to advance immunotherapies across a wide range of infectious diseases and tumor types.
Inovio Pharmaceuticals, Inc. - INOVIO Receives FDA Feedback …
WEBOct 10, 2023 · INO-3107 is INOVIO's lead DNA medicine product candidate and is being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types responsible for causing RRP among other HPV-related diseases.
Inovio Pharmaceuticals - Wikipedia
WEBInovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases.
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA ...
WEBDec 14, 2021 · INOVIO has clinically shown that a DNA vaccine candidate can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18.
INOVIO Announces U.S. FDA Breakthrough Therapy Designation …
WEBSep 7, 2023 · INO-3107 is INOVIO's clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV-6...
Inovio Pharmaceuticals, Inc. - INOVIO Receives Regulatory …
WEBSep 22, 2021 · INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response.
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE …
WEBNov 9, 2021 · INOVIO is the first company to have clinically demonstrated that a DNA vaccine candidate can be delivered directly into cells in the body via a proprietary smart device to produce a robust and...
INOVIO Receives Authorization to Conduct Phase 3 Efficacy …
WEBAug 26, 2021 · INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable...
Skip to content